0:00
/
Preview

The Road to Rescheduling: Why I’m Holding My Ground in MSOS 🌿

Breaking down the post-hearing DEA timeline, institutional risk aversion, and my USIC portfolio log

Hey Gang,

July has been a tough month on the tape for cannabis, with $MSOS down ~15% month-to-date and back near the lower bounds of its year-long trading range.

When a sector gets beat down like this, it is easy to get shaken out by short-term noise. But if you look under the hood at the regulatory catalyst sequence, the underlying thesis remains completely intact.

I still firmly believe $MSOS is on track to break out of this base and target the $10 level by year-end, and I am positioned accordingly in the Money Manager division of the US Investing Championship.

Here is a quick recap of where we stand today and why the next 30 to 60 days are critical:

  • Current Price Action: $MSOS has retested the exact support levels from August 2025, when the initial rescheduling conversation gained momentum. We are essentially at the bottom of a wide, 1-year consolidation base.

  • The High-Conviction Bet: Despite recent drawdowns, this trade represents a core allocation across my equity and options books for the USIC. In trading, sometimes you have to be willing to “win ugly” and adapt to the timeline rather than panic out at the bottom.

User's avatar

Continue reading this post for free, courtesy of Andrew O'Connell, CFA, FRM.